Stockreport

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

Monopar Therapeutics Inc.  (MNPR) 
PDF WILMETTE, Ill., June 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovati [Read more]